Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

60 trials with published results (15%)

Research Maturity

228 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.4%

30 terminated out of 403 trials

Success Rate

88.4%

+1.8% vs benchmark

Late-Stage Pipeline

15%

60 trials in Phase 3/4

Results Transparency

26%

60 of 228 completed with results

Key Signals

60 with results88% success30 terminated

Data Visualizations

Phase Distribution

255Total
Not Applicable (67)
Early P 1 (3)
P 1 (47)
P 2 (78)
P 3 (46)
P 4 (14)

Trial Status

Completed228
Unknown97
Terminated30
Withdrawn17
Active Not Recruiting15
Recruiting11

Trial Success Rate

88.4%

Benchmark: 86.6%

Based on 228 completed trials

Clinical Trials (403)

Showing 20 of 20 trials
NCT06631287Phase 3Recruiting

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT07834073Phase 4Completed

Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity

NCT04964115Active Not Recruiting

Post Acute Sequelae of COVID-19

NCT05683353Active Not RecruitingPrimary

Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

NCT05897541Phase 3CompletedPrimary

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

NCT05534048Phase 3WithdrawnPrimary

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

NCT06147063Phase 1Completed

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

NCT06247059Not ApplicableWithdrawnPrimary

Reducing Respiratory Virus Transmission in Bangladeshi Classrooms

NCT05305547Phase 3CompletedPrimary

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT06810934Phase 1Recruiting

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

NCT04910269Phase 3Terminated

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT05113836CompletedPrimary

LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2

NCT07222384Phase 3Completed

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT05384561Not ApplicableRecruiting

Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19

NCT04868903Not ApplicableCompletedPrimary

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT04903132Active Not RecruitingPrimary

Cellular Senescence and COVID-19 Long-Hauler Syndrome

NCT05125887CompletedPrimary

Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2)

NCT07659847Recruiting

Cardiovascular Assessment 5 Years After MIS-C

NCT05855434CompletedPrimary

The ACDC Study Assessing Cognitive Deterioration in COVID-19

NCT07079670Phase 3Completed

Safety and Immunogenicity of NVX-CoV2705

Scroll to load more

Research Network

Activity Timeline